Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Liabilities and Shareholders Equity (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $53.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 39.6% to $53.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $260.9 million, a 15.09% decrease, with the full-year FY2024 number at $76.4 million, up 14.87% from a year prior.
  • Liabilities and Shareholders Equity was $53.6 million for Q3 2025 at Mereo BioPharma, down from $62.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $170.4 million in Q4 2021 to a low of $53.6 million in Q3 2025.
  • A 5-year average of $81.6 million and a median of $72.4 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 105.02% in 2021, then crashed 54.57% in 2022.
  • Mereo BioPharma's Liabilities and Shareholders Equity stood at $170.4 million in 2021, then plummeted by 54.57% to $77.4 million in 2022, then fell by 14.1% to $66.5 million in 2023, then increased by 14.87% to $76.4 million in 2024, then fell by 29.83% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Liabilities and Shareholders Equity are $53.6 million (Q3 2025), $62.6 million (Q2 2025), and $68.3 million (Q1 2025).